AU602961B2 - Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions - Google Patents

Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions Download PDF

Info

Publication number
AU602961B2
AU602961B2 AU13160/88A AU1316088A AU602961B2 AU 602961 B2 AU602961 B2 AU 602961B2 AU 13160/88 A AU13160/88 A AU 13160/88A AU 1316088 A AU1316088 A AU 1316088A AU 602961 B2 AU602961 B2 AU 602961B2
Authority
AU
Australia
Prior art keywords
methyl
probucol
compound
carbon atoms
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU13160/88A
Other languages
English (en)
Other versions
AU1316088A (en
Inventor
Niall Doherty
George Ku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of AU1316088A publication Critical patent/AU1316088A/en
Application granted granted Critical
Publication of AU602961B2 publication Critical patent/AU602961B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU13160/88A 1987-03-17 1988-03-16 Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions Expired AU602961B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2658687A 1987-03-17 1987-03-17
US026586 1987-03-17
US15157288A 1988-02-18 1988-02-18
US151572 1988-02-18

Publications (2)

Publication Number Publication Date
AU1316088A AU1316088A (en) 1988-09-15
AU602961B2 true AU602961B2 (en) 1990-11-01

Family

ID=26701419

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13160/88A Expired AU602961B2 (en) 1987-03-17 1988-03-16 Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions

Country Status (10)

Country Link
EP (1) EP0292660B1 (enExample)
JP (1) JP2671129B2 (enExample)
KR (1) KR960005704B1 (enExample)
AU (1) AU602961B2 (enExample)
DE (1) DE3869202D1 (enExample)
DK (1) DK175801B1 (enExample)
ES (1) ES2039489T3 (enExample)
GR (1) GR3004108T3 (enExample)
IE (1) IE60708B1 (enExample)
PH (1) PH23885A (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959392A (en) * 1989-07-24 1990-09-25 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus
AU651873B2 (en) * 1991-03-18 1994-08-04 Merrell Dow Pharmaceuticals Inc. Method of inhibiting the progressive development of diabetes mellitus
FI951367A7 (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
EP1695959A1 (en) * 1997-05-14 2006-08-30 Atherogenics, Inc. Compouds and methods for the inhibition of the expression of VCAM-1
ATE356113T1 (de) 1997-05-14 2007-03-15 Atherogenics Inc Probucolbernsteinsäureester zur hemmung der expression von vcam-1
AU2006202461B2 (en) * 1997-05-14 2009-12-03 Atherogenics, Inc. Compositions and methods for the inhibition of the expression of VCAM-1
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
AU8282798A (en) 1997-07-01 1999-01-25 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
AU5340101A (en) 2000-04-11 2001-10-23 Atherogenics Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
EP2139320A4 (en) 2007-03-26 2010-09-08 Salutria Pharmaceuticals Llc METHODS AND COMPOSITIONS OF PROBUCOL DERIVATIVES FOR THE TREATMENT OF DIABETES
CN108299263B (zh) * 2018-01-30 2020-12-01 北京德默高科医药技术有限公司 一种普罗布考衍生物及其制备方法与应用

Also Published As

Publication number Publication date
IE60708B1 (en) 1994-08-10
IE880786L (en) 1988-09-17
EP0292660A3 (en) 1990-03-28
DK143388D0 (da) 1988-03-16
DK143388A (da) 1988-09-18
KR960005704B1 (ko) 1996-05-01
PH23885A (en) 1989-12-18
DE3869202D1 (de) 1992-04-23
ES2039489T3 (es) 1993-10-01
AU1316088A (en) 1988-09-15
JP2671129B2 (ja) 1997-10-29
JPS63258408A (ja) 1988-10-25
EP0292660A2 (en) 1988-11-30
EP0292660B1 (en) 1992-03-18
GR3004108T3 (enExample) 1993-03-31
DK175801B1 (da) 2005-02-28
KR880010766A (ko) 1988-10-24

Similar Documents

Publication Publication Date Title
US4975467A (en) Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
Brinckerhoff et al. Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cis-retinoic acid
US6410588B1 (en) Use of cannabinoids as anti-inflammatory agents
US8455553B2 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease and transplant rejection
US4870101A (en) Method of inhibiting interleukin-1 release
EP0292660B1 (en) Alkylidenedithiobis (substituted) phenols for inhibiting interleukin-1 release and for alleviating interleukin-1 mediated conditions
US4997850A (en) Treating agent for osteroarthritis
EP1061932B1 (en) Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
FR2622106A1 (fr) Nouvelle application therapeutique de derives du 4h-benzo(4,5)cyclo-hepta(1,2-b)thiophene
CN1200106A (zh) 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药
AU601554B2 (en) Method of inhibiting interleukin-1 release
JP2004503464A (ja) 糖尿病および関連する状態を治療するための新規化合物
US5789446A (en) Therapeutic agent for treating joint diseases associated with arthritis
US4338334A (en) 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
SE453637B (sv) Anvendning av derivat av aminobensoesyra for framstellning av en farmaceutisk komposition med forhindrande eller aterstellande effekt pa stenokardi, arrytmi, cerebral infarkt, myokardial infarkt, cerebral apoplexi eller
US5034412A (en) Method of inhibiting interleukin-1 release
US5011857A (en) Method of inhibiting interleukin-1 release
ES2241182T3 (es) Procedimiento de inhibicion de la produccion de citocinas.
US5310749A (en) Antiprotozoal composition containing a 2-nitroimidazole derivative and method thereof
US5453444A (en) Method to mitigate or eliminate weight loss
JPH0551319A (ja) インターロイキン１産生促進剤
JPH1067653A (ja) 関節疾患治療剤
Kidd et al. AMOEBICIDAL ACTIVITY OF DICHLORO‐N‐2‐HYDROXY‐ETHYL‐N‐p‐METHYLSULPHONYLBENZYLACETAMIDE AND SOME RELATED COMPOUNDS
CN119258058A (zh) C35h39n3o3小分子化合物或其衍生物在制备治疗自身免疫性疾病药物中的应用
US3714362A (en) Acetic acid derivatives as hypolipidemics